research centers


Search results: Found 28

Listing 1 - 10 of 28 << page
of 3
>>
Sort by

Article
The response to Growth Hormone Therapy in Isolated Growth Hormone Deficiency

Authors: Dr. Sura Y. Noory, --- Deia K. Kalaf, --- Refaat M. Abdul Hussain
Journal: Karbala Journal of Medicine مجلة كربلاء الطبية ISSN: 19905483 Year: 2009 Volume: 2 no.6, 7 Issue: 4 Pages: 409-419
Publisher: Kerbala University جامعة كربلاء

Loading...
Loading...
Abstract

objective: to study the response of Growth hormone therapy in children with short staturedue to isolated growth hormone deficiency.Sample: six hundred forty eight patient with short stature were enrolled in this study.Method: six hundred forty eight patient with short stature attending Central Teaching Hospitalfor children Baghdad/ Iraq, were recorded and all patients were investigated to exclude otherdisease like diabetes, hypothyroidism, celiac disease, turner syndrome, renal failure,achondroplasia,..etc. with a total of 48 patients due to these causes were excluded from the study.So the remaining patients were 600 only those exposed to our study. All children investigated forgrowth hormone basal level and after provocation by clonidine done for one time .Results: We found that the basal level of growth hormone was less 0.5 microgram (μg)/liter (L),0.5 -1 μg/liter and more than 1 μg /liter in 25%, 38% and 37% respectively in our sample, whilethe results after provocation were less than 5, 5-10 and more than 10 μg /liter in 60%, 28% and12% respectively in our sample. The effect of growth hormone in one year therapy theincrement in height was less than 4 cm in 22% of our patients, from 4-8 cm in 50%, and morethan 8 cm in 28 % and we found that the male patients were 384(64%), and the female patientswere 216(36%),with peak difference between bone age and chronological age was more than 2year for both sex and most of the patientsُ age was more than 15 years.Conclusion: Most patients with isolated growth hormone deficiency had basal growth hormonelevel 0.5 – 1μg/L, while the provocation level was less than 5μg/L and the effect of growthhormone therapy on height maximally 4-8 cm in proximately 50% of the patients and more than8 cm in 28% after one year treatment. Patients with isolated Gh deficiency showed goodresponse to therapy with growth hormone recombinant in a dose 0.1 mg /kg /day

Keywords

Gh --- Growth hormone


Article
Effect of Human Growth Hormone (HGH) on Children with Achondroplasia (ACH)
تأثير هورمون النمو على الاطفال المصابين بمرض الودانة

Authors: A. G. Al-Rawi د. عبد الغني الراوي --- Mona Abdulghani د. منى عبد الغني الراوي
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2006 Volume: 19 Issue: 2 Pages: 151-157
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Abstract:Back ground: This study, we evaluate the effectiveness of using recombinant GH for ten Achondroplastic children.Patient & method: the children. (7 females, 3 males) with typical features of achondroplasia, 4-14 years age, participated in this study. Physical and anthropometric measurements were taken every 3 moths, 12 months before and 12 months during GH therapy.Results: for children less than 10 year of age, the mean growth rate is increased from 3.4±0.4cm/year in the pretreatment period to 8±1.1 cm/year during the first year of GH treatment. For children more than 10 years of age, the mean growth rate is increased from 3.2± 0.6 cm/year in the pretreatment period to 5.6± 1.3 cm/year during the first year of GH treatment.Conclusion: this study and several other studies confirmed that GH therapy is beneficial in the treatment of short stature in children with Achondroplasia (during the first year of treatment), how ever, is still premature to conclude that the GH will improve the adult height.Key words: Growth hormone & achondroplasia

الملخص: هدف البحث : في هذه الدراسة تم تقييم استعمال هرمون النمو على عشرة اطفال مصابين بمرض الودانة.المرض وطريقة البحث: اشترك في هذا البحث عشرة اطفال ( 7 بنات وثلاثة اولاد) يحملون صفات الودانة النمطي. اعمارهم تتراوح بين (4-14) سنة.الفحص والقياسات البشرية: القياسات البشرية والفحص اجريت كل ثلاثة اشهر. اثنا عشر شهرا قبل واثناء عشر شهرا اثناء اعطاء العلاج.النتائج: ارتفع معدل النمو في الاطفال دون سن العشر سنوات من 3,4 سم في السنة في الفترة قبل مباشرة العلاج هلى 8سم في السنة خلال فترة العلاج.بينما ارتفع معدجل النمو في الاطفال بعد سن (10 سنوات ) من 3,2 سم / السنة في الفترة قبل العلاج الى 5,6 سم في السنة خلال فترة العلاج.الاستنتاج: هذا البحث وبحوث عديدة اخرى تؤكد ان علاج الاطفال المصابين بمرض الودانة بهرمون النمو ذو فائدة في السنة الاولى من بدأ العلاج ولكن لانستطيع التأكد بصورة قطعية عن فائدته عند البلوغ.


Article
Effect of aging on growth hormone-leptin axis in normal andobese healthy subjects

Authors: Hedef D. El-Yassin --- Zaineb A. Razak Al-Sharifi (
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: 00419419 Year: 2008 Volume: 50 Issue: 3 Pages: 383-390
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Growth hormone is a hormone responsible for the normal body
growth and development by stimulation protein production in muscle cells and
energy release for breakdown of fat. On the other hand leptin is a newly discovered
hormone that is mainly synthesized in adipose tissues it decreases food intake by
causing satiety and promoting energy combustion . Both aging and obesity are
associated with a reduction in growth hormone secretion. In the mean time obese
humans have increased circulating leptin.
Objective: The aim of this paper is to shed light on the contribution of these two
hormones in the mechanism of aging process in an attempt of improving this
process for a better life at old ages.
Subjects and methods: Two hundred and seventy healthy subjects aged 25-64
years old participated in this study. The subjects' were divided into four groups
according to their ages and to three groups according to their weights. Urine
analysis from each subject was carried out to exclude diabetes and renal failure.
Sera from blood samples were used to carry out certain biochemical parameters and
hormone (growth hormone and leptin).
Results: The results obtained show a decrease in the level of growth hormone with
progression of age. In the mean time there is an increase in the level of serum leptin
with the advancement of age. Aging is usually associated with adiposity. Increasing
fat with age is probably multifactorial one potential mechanism for that is reduced
leptin transport across blood-brain barrier..
Conclusion: The increase in leptin level which was observed in elderly age group
and obese group suggest that the associated decrease in growth hormone serum
level is related to obesity in general and in particular to the aging process.

Keywords

growth hormone --- leptin --- obesity --- aging.


Article
Evaluation of The Response of Children with Short Stature to A Six Months Treatment with Recombinant Human Growth Hormone

Author: Abdulabbas Abduon Hadi
Journal: Karbala Journal of Medicine مجلة كربلاء الطبية ISSN: 19905483 Year: 2016 Volume: 9 Issue: 2 Pages: 2569-2574
Publisher: Kerbala University جامعة كربلاء

Loading...
Loading...
Abstract

background: Human Growth hormone (GH) is 191amino acids protein , gene located on long arm of chromosome 17. its secretion is under control of 2 hypothalamic hormones: growth hormone releasing hormone(GHRH) and somatostatin. Growth hormone is a major promoter of anabolism, its effects on growth are believed to be indirect ,being mediated through peptides called somatomedins or insulin-like growth factors (IGFs) that in turn mediate many of the growth promoting effects of Growth hormone . Recent advances have focused on biological actions of IGFs & their six well defined binding proteins (IGFBPs), the major one is IGF-BP3 which decreased in GH-deficient children. IGFs are GH-dependent serum peptide with potent metabolic & mitogenic activities believed to be responsible for growth effects of GH, they stimulate cellular replication & differentiation . Objective: To evaluate the difference in the response of the children with short stature (of different causes) to a six months treatment with recombinant human GH .Patients And Methods: this is a prospective study in which a total no. of 84 pt (with age ranging from 4-20 years) were included. They were presenting to the endocrine clinic in Al-Mansour teaching hospital for children in 2002 with short stature & growth delay. After the final diagnosis was made, all pt were treated by recombinant GH (in a dose of 0.1-0.2 unit/kg / day) by subcutaneous or intramuscular route at night time (7-8pm) , After completing 6 months of treatment with GH, the patients were evaluated again for height and height velocity, weight, bone age, height age, sexual maturity rate, testicles and phallus in male. Results: There was no significant difference in response to the therapy between male and female ; the mean height velocity in male was 9.37 +/-3.99 cm / year (ranging from 1-19 cm) and the mean height velocity in female was 9.90 +/-4.39 cm / year ranging from 3-20 cm . Conclusion: Growth hormone therapy is effective in increasing the height velocity in most patients with short stature and it should be initiated as early as possible to improve height as much as possible.


Article
Insulin-Like Growth Factor-1 (IGF-1) Predicte the Diagnosis of Growth Hormone Deficincy in Short Prepubertal Children

Authors: Abdul Kareem Y. Al-Samarraie --- Ali A. Ali --- Maan A. J. Bahrani
Journal: Iraqi Journal of Pharmaceutical Sciences المجلة العراقية للعلوم الصيدلانية ISSN: 16833597 Year: 2011 Volume: 20 Issue: 2 Pages: 54-58
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

To study the serum IGF-1 level for prediction of growth hormone deficiency and its role in the diagnosis of short stature in children and adolescents. A study was conducted on forty four (44) short children with growth hormone deficiency. Children were classified into Group I thirty five (35) prepubertal children and Group II (9) patients who entered puberty. In addition to forty (40) apparently healthy children as control group, also were divided into group I control(29) prepubertal &group II (11) pubertal . IGF-1,GH ,Thyroid function ,serology for celiac disease , Hb level ,bone age were done for all patients. IGF-1 and basal GH level (without provocative test) were done for control . There was a significant low difference between the serum IGF-1 level in the patients of group I in comparison to their serum level in control group I {(90.98±23.69) (121.83±23.69) (p<0.05)} . While there was no such difference between the serum IGF-1 level in the patients of group II in comparison to their serum level in control group II {(184.59±196.52) (285.91±68.89) (p<0.05)}. This study shows that IGF-1 level is low compared to control in short GH deficient children who did not enter puberty, while it is less significant in children and adolescents who entered puberty. So IGF-1 is a suitable parameter to predict GH deficiency in short prepubertal children in whom GH deficiency was found by GH provocative testing. But this test is less reliable in children who entered puberty.

ھو دراسة مستوى ھرمون في المصل في تشخیص قصر IGF-1 للتحقق من نقص ھرمون النمو وبیان دور ھرمون 1 IGF- في تشخيص قصرالقامة عند الأطفال والمراھقین . تم إجراء الدراسة على 44 طفلا قصیر القامة والذین لدیھم نقص في ھرمون النمو.حیث تم تصنیفھاإلى مجموعتین الأولى وتضم 35 طفلا في مرحلة ما قبل البلوغ والمجموعة الثانیة و تضم 9 أطفال دخلو مرحلة البلوغ بالإضافة إلىIGF- 40 من الأطفال الأصحاء قسموا إلى مجموعة أولى لم یبلغوا ( 29 ) ومجموعة ثانیة دخلوا البلوغ( 11 ). وتم قیاس ھرمون 1IGF- ,ھرمون النمو, ھرمونات الغدة الدرقیة, اختبار حساسیة الحنطة , مستوى الھیموغلوبین وعمر العظم لجمیع المرضى.وقیاس 1في مصل مرضى المجموعة الأولى ھو IGF - وھرمون النمو یدون فحص تحفیزي للأطفال الأصحاء. معدل مستوى ھرمون 1(121,83± في مصل المجموعة القیاسیة الأولى ھو ( 23,69 IGF- 90.98±23.96 ) نانوغرام/ ملیلیتر بینما معدل ھرمون 1 )في IGF- في حین ان معدل مستوى ھرمون 1 ( p< نانوغرام /ملیلیتر والتي تظھر أن ھناك فرقا ملحوظا بین المجموعتین ( 0.05في مصل المجموعة القیاسیة IGF- 184,59 ) نانوغرام /ملیلیتر بینما معدل ھرمون 1 ± مصل مرضى المجموعة الثانیة ھو( 196,52من خلال ھذه .( p> 285,91 ) نانوغرام /ملیلیتر والتي تظھر أن ھناك فرق غیر ملحوظ بین المجموعتین( 0.05 ± الثانیة ھو ( 68,89في مصل الأطفال قصار القامة الغیر بالغین منخفض بشكل ملحوظ مقارنة مع المجموعة IGF- الدراسة تبین أن نسبة ھرمون 1القیاسیة الأولى بینما لا یوجد فرق في نسبة الھرمون في مصل الأطفال والمراھقین مقارنة مع المجموعة القیاسیة الثانیة.لذلك فان نسبةھو مقیاس مناسب للتنبؤ بنقص ھرمون النمو في الأطفال قصیري القامة الذین لم یصلوا البلوغ والذین تم الكشف عن IGF- ھرمون 1 IGF- نقص ھرمون النمو لدیھم بالفحص التحفیزي لھرمون النمو. ولكن ھرمون1 یعتبر اقل اعتمادا للأطفال الذین وصلوا البلوغ.


Article
Response of Height Measurements to Growth hormone therapy in Short Children with Growth hormone Deficiency
استجابةّ مقاييسِ الطول للمعالجة بهرمون النمو لقصار الأطفال المصابين بنقص هورمون النمو ا وغيره

Authors: Najla I. M. Said د.نجلة ابراهيم محمد سعيد --- Ghada F. Naji د. غادة فايق ناجى
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2006 Volume: 19 Issue: 3 Pages: 220-224
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Abstract:Background: longitudinal assessment of growth is essential child care.Objective: to find out the response of growth in term of the number of the standard deviations below the mean of height for age and sex (Z score) (HAZ) to the recombinant human growth hormone therapy in short children with growth hormone deficiency and others.Patients & Methods: A prospective study was done on 325 children; their age range was 1-19years, referred to growth hormone clinic of Central Teaching Hospital for Children / Baghdad with short-stature for their age or with slow growth. The study included only those children on regular recombinant human growth hormone (rhGH) therapy for (6 months - 4 years), for the period between 1st of October 1997 till 1st of March 2003. Evaluation included: detailed medical history, physical examination (included height measurements) and laboratory tests such as blood count, general urine examination, thyroid function, growth hormone assay (basal and after simulation with clonidine 75-100mcg/m2), bone age and chromosomal analysis from peripheral blood, and those who were diagnosed as growth hormone deficiency, were commenced on growth hormone therapy in a dose of (0.24-0.3 mg / kg /wk). Results: has shown a highly significant increase in the Z-score of height for age (HAZ) of children with growth hormone deficiency in response to (rhGH) therapy in a dose (0.24-0.3mg/kg/wk) from (-4.28+1.99) to (-1.86+2.48), while the patients with Turner syndrome from (-4.33+2.02) to (-1.94+2.52), when treated with (rhGH) in a dose (0.3-0.37mg/kg/wk), so as in patients with growth hormone deficiency and celiac disease who were on gluten free diet for one year, but the response was less in children with achondroplasia or with others like Down syndrome and Silver-Russell syndrome. The response was more significant in the prepubertal than pubertal age groups.Conclusion: earlier identification of short children due to growth hormone deficiency & earlier treatment to have a better response & similarly earlier identification of short females with Turner syndrome.Key words: growth hormone deficiency, height measurement, short stature

الملخصالخلفية: التقييم الطولى للنمو يعتبر من ضمن الرعاية الطفولية الأساسية.إنّ هدفَ هذه الدراسةِ هو لمعرفة استجابة النمو في تعبيرِ عددِ الإنحرافات المعيارية تحت متوسطِ الطولِ للعُمرِ والجنسِ (Z score ) (HAZ) للمعالجة بهرمون النمو البشرى المصنع (rhGH) لقصار الأطفال المصابين بنقص هورمون النمو او غيره . المرضى والوسائل: هده دراسة متوقّعة تضمنت 325 طفلِ تمت احالتهم إلى عيادةِ هورمونِ النمو فى مستشفى الطفل المركزى التعليمىِ / بغداد لمعاناتهم من قصر القامة ِبالنسبة لعُمرِهم أَو بالنمو البطيئِ. تَضمّنتْ الدراسةُ أولئك الأطفالِ المستلمين علاج هورمونِ النمو البشرى المصنع (rhGH) بشكل منتظم للفترة بين (6 شهورِ - 4 سَنَوات) فقط، والدين تتراوح اعمارهم من ( سنة واحدة الى 19سنة ), للفترةِ بين أولِ مِنْ أكتوبر/تشرين الأولِ 1997 حتى أولِ مِنْ مارس/آذارِ 2003. التقييم تَضمّنَ: التأريخ الطبي المُفصّل، الفحص السريرى (تَضمّنَ مقاييسَ الطول), والفحوصات المختبرية مثل فحص الدمِّ، فحص الأدرار العامِّ، وظائف الغدة الدرقّية، تحليل هورمونِ النمو (أساسي وبعد التحفيز مَع clonidine 75-100 mcg /m 2)، عُمر العظم وإختبار الكروموسومِ. وأولئك الذين شخّصوا كنقص هورمونِ النمو، با شر لهم علاج هورمون النمو بجرعة مقدارها (0.24-0.3ملغم / كيلوغرام / اسبوع).النَتائِج: أظهرت النتائج زيادة هامّة جداً في (Z score) الطول بالنسبة للعُمرِ(HAZ) للأطفالِ المصابين بنقصِ هورمونِ النمو استجابة لعلاج (rhGH) بجرعة مقدارها (0.24-0.3 ملغم / كيلوغرام / اسبوع) مِنْ (-4.28+1.99) إلى (-1.86+2.48)، بينما لمرضى متلازمة Turner(Turner syndrome) مِنْ (-4.33+2.02) إلى (-1.94+2.52)، عندما عولجوا (rhGH) بجرعة مقدارها (0.3-0.37 ملغم / كيلوغرام / اسبوع).وكدلك الزيادة هامة جدا بالنسبة للمرضى المصابين بنقصِ هورمونِ النمو ومرضِ حساسية الحنطة ( ( celiacالذين اتبعوا حمية لمدة سنة ( تغدية خالية من الغلوتين, الدابوق ) .لكن الزيادة كانت اقل بالنسبة للأطفالِ المصابين بنقص التعظّم الغضروفي ا و مَع الآخرين مثل (مرض المغولية) متلازمة Down ومتلازمة Silver-Russell . الأستجابةّ كَانتَ أكثرَ أهمّية في مجموعة قَبْلَ البلوغيِ مِنْ مجموعةِ الأعمار البلوغيةِ. الاستنتاجات : التشخيص المبكر لقصر القامة فى الأطفالِ بسبب نقصِ هورمونِ النمووكدلك للاناث القصيرات بسبب متلازمة Turner ومعالجةِ مبكرة للحصول على نتيجة افضل.


Article
Relationship between Leptin and Insulin‐like Growth Factor‐1

Author: Noor Thair Tahir
Journal: Mustansiriya Medical Journal مجلة المستنصرية الطبية ISSN: 20701128 22274081 Year: 2014 Volume: 13 Issue: 2 Pages: 61-65
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Growth hormone deficiency (GHD) is suspected insubjects with short stature (SS) and reduced growth velocity in whomother causes of poor growth have been excluded. Insulin‐like growthfactor‐1 (IGF‐1) measurements are relatively newer methods forevaluating GHD or GH adequacy.Objective: To study the relation between levels of leptin and IGF‐1 in thechildren and adolescents in whom GHD was found.Patients and Methods: This study was conducted during the periodfrom June 2013 until the end of March 2014. The patients wereattending to the National Diabetic Center/ AL‐Mustansiriya University.Serum IGF‐1 and leptin were measured in children and adolescent withGHD; 56 children with GHD were participated in this study their agerange was (5‐17) years, they were compared with 30 healthy children ascontrol group. Results:Means BMI and basal serum levels of GH and IGF‐1 were significantlydecreased in children and adolescent with GHD when compared withthe control group. There was a significant decrease in serum level ofIGF‐1 in boys with GHD as compared to girls with GHD, while there wasno significant difference in basal GH and leptin between boys and girlswith GHD. A significant negative correlation was found between leptinversus BMI and IGF‐1 in both gender groups, while a significant positivecorrelation was found between serum IGF‐1 versus BMI and GH inchildren with GHD.Conclusions: The present results are consistent with the hypothesisthat leptin could contribute to the regulation of GH secretion and IGF‐1concentrations.


Article
Response of Height Measurements to Growth hormone therapy in Short Children with Growth hormone Deficiency and Others.
استجابةّ مقاييسِ الطول للمعالجة بهرمون النمو لقصار الأطفال المصابين بنقص هورمون النمو ا وغيره

Authors: Najla I. M. Said نجله ابراهيم محمد --- Ghada F. Naji غاده فايق
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2005 Volume: 18 Issue: 3 Pages: 266-271
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Abstract:Background: longitudinal assessment of growth is essential child care.Objective: to find out the response of growth in term of the number of the standard deviations below the mean of height for age and sex (Z score) (HAZ) to the recombinant human growth hormone therapy in short children with growth hormone deficiency and others.Patients & Methods: A prospective study was done on 325 children, their age range was 1-19years, referred to growth hormone clinic of Central Teaching Hospital for Children / Baghdad with short-stature for their age or with slow growth. The study included only those children on regular recombinant human growth hormone (rhGH) therapy for (6 months - 4 years), for the period between 1st of October 1997 till 1st of March 2003. Evaluation included: detailed medical history, physical examination (included height measurements ) and laboratory tests such as blood count, general urine examination, thyroid function, growth hormone assay (basal and after stimulation with clonidine 75-100mcg/m2), bone age and chromosomal analysis from peripheral blood, and those who were diagnosed as growth hormone deficiency, were commenced on growth hormone therapy in a dose of (0.24-0.3 mg / kg /wk). Results: has shown a highly significant increase in the Z-score of height for age (HAZ) of children with growth hormone deficiency in response to (rhGH) therapy in a dose (0.24-0.3mg/kg/wk) from (-4.28+1.99) to (-1.86+2.48), while the patients with Turner syndrome from (-4.33+2.02) to (-1.94+2.52), when treated with (rhGH) in a dose (0.3-0.37mg/kg/wk), so as in patients with growth hormone deficiency and celiac disease who were on gluten free diet for one year, but the response was less in children with achondroplasia or with others like Down syndrome and Silver-Russell syndrome.The response was more significant in the prepubertal than pubertal age groups. Conclusion: earlier identification of short children due to growth hormone deficiency & earlier treatment to have a better response & similarly earlier identification of short females with Turner syndrome.

الملخص:الخلفية: التقييم الطولى للنمو يعتبر من ضمن الرعاية الطفولية الأساسية.الهدف:إنّ هدفَ هذه الدراسةِ هو لمعرفة استجابة النمو في تعبيرِ عددِ الإنحرافات المعيارية تحت متوسطِ الطولِ للعُمرِ والجنسِ (Z score ) (HAZ) للمعالجة بهرمون النموالبشرى المصنع (rhGH) لقصار الأطفال المصابين بنقص هورمون النمو او غيره . المرضى والوسائل: هده دراسة متوقّعة تضمنت 325 طفلِ تمت احالتهم إلى عيادةِ هورمونِ النمو فى مستشفى الطفل المركزى التعليمىِ / بغداد لمعاناتهم من قصر القامة ِبالنسبة لعُمرِهم أَو بالنمو البطيئِ. تَضمّنتْ الدراسةُ أولئك الأطفالِ المستلمين علاج هورمونِ النمو البشرى المصنع (rhGH) بشكل منتظم للفترة بين (6 شهورِ - 4 سَنَوات) فقط، والدين تتراوح اعمارهم من ( سنة واحدة الى 19سنة ), للفترةِ بين أولِ مِنْ أكتوبر/تشرين الأولِ 1997 حتى أولِ مِنْ مارس/آذارِ 2003. التقييم تَضمّنَ: التأريخ الطبي المُفصّل، الفحص السريرى (تَضمّنَ مقاييسَ الطول), والفحوصات المختبرية مثل فحص الدمِّ، فحص الأدرار العامِّ، وظائف الغدة الدرقّية، تحليل هورمونِ النمو (أساسي وبعد التحفيز مَع clonidine 75-100 mcg /m 2)، عُمر العظم وإختبار الكروموسومِ. وأولئك الذين شخّصوا كنقص هورمونِ النمو، با شر لهم علاج هورمون النمو بجرعة مقدارها (0.24-0.3ملغم / كيلوغرام / اسبوع).النَتائِج: أظهرت النتائج زيادة هامّة جداً في (Z score) الطول بالنسبة للعُمرِ(HAZ) للأطفالِ المصابين بنقصِ هورمونِ النمو استجابة لعلاج (rhGH) بجرعة مقدارها (0.24-0.3 ملغم / كيلوغرام / اسبوع) مِنْ (-4.28+1.99) إلى (-1.86+2.48)، بينما لمرضى متلازمة Turner(Turner syndrome) مِنْ (-4.33+2.02) إلى (-1.94+2.52)، عندما عولجوا (rhGH) بجرعة مقدارها (0.3-0.37 ملغم / كيلوغرام / اسبوع).وكدلك الزيادة هامة جدا بالنسبة للمرضى المصابين بنقصِ هورمونِ النمو ومرضِ حساسية الحنطة ( ( celiacالذين اتبعوا حمية لمدة سنة ( تغدية خالية من الغلوتين, الدابوق ) .لكن الزيادة كانت اقل بالنسبة للأطفالِ المصابين بنقص التعظّم الغضروفي ا و مَع الآخرين مثل (مرض المغولية) متلازمة Down ومتلازمة Silver-Russell . الأستجابةّ كَانتَ أكثرَ أهمّية في مجموعة قَبْلَ البلوغيِ مِنْ مجموعةِ الأعمار البلوغيةِ. الاستنتاجات : التشخيص المبكر لقصر القامة فى الأطفالِ بسبب نقصِ هورمونِ النمووكدلك للاناث القصيرات بسبب متلازمة Turner ومعالجةِ مبكرة للحصول على نتيجة افضل.


Article
Histological changes induced by exogenous human growth hormone in the thymus of male albino mice

Authors: Sameh S. Akkila --- Salman S. Salman
Journal: Mustansiriya Medical Journal مجلة المستنصرية الطبية ISSN: 20701128 22274081 Year: 2006 Volume: 6 Issue: 2 Pages: 65-77
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

It is well documented that hormones of the pituitary gland affect lymphoid organs both structurally and physiologically. This experiment has been conducted to practically confirm the effect of Growth Hormone (a major pituitary hormone) on the histological changes that occur in the thymus (a primary lymphoid organ) in relation to age-related and steroid-induced atrophy.Male albino mice of 8, 28 and 41 weeks of age were used. Each age group was subdivided into 4 subgroups, two of which as controls while the other two received human Growth Hormone for one and two week periods. The young mice were given high dose Dexamethasone to induce thymic atrophy before starting Growth Hormone treatment. Growth Hormone was given as a single daily subcutaneous injection in the morning.Statistical analysis of the results and histological examination of the GH-treated groups revealed that GH was effective in restoring histological structure and possibly the function of the thymus following steroid-induced and age-related atrophy. This was evident by the finding of deceleration of fatty infiltration of thymic tissue and maintenance of the clear thymic architecture, increased thymic weight/ body weight ratio and increased numbers of thymocytes and epitheliocytes in cortical and medullary zones.


Article
In vivo immunohistochemical investegation of bone deposition at collagen coated Ti implant surface

Authors: Ban A. Al-Ghani بان الغاني --- Athraa Y.Al-Hijazi عذراء يحيى الحجازي --- Thair L.AL-Zubaydi Thair L.AL-Zubaydi
Journal: Journal of baghdad college of dentistry مجلة كلية طب الاسنان بغداد ISSN: 16800087 Year: 2011 Volume: 23 Issue: special issue Pages: 47-52
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Dental implants provide a unique treatment modality for the replacement of lost dentition. Functionalsurface modifications by organic material such as collagen coating seem to enhance early peri-implant boneformation, enhancing the initial cell attachment. The aim of the study was to study the expression of osteocalcin andgrowth hormone receptor as bone formation markers in collagen coated and uncoated implant in intervalperiods(2,and 6 weeks).Materials and Methods: Commercially pure Titanium(cpTi) implants, coated with collagen protein, were placed inthe tibias of 32 New Zealand white rabbits, immunohistochemical tests for detection of expression of osteocalcin andgrowth hormone receptor were performed on all the implants of both control and experimental groups for (2, and 6weeks) healing intervals. Mechanical test (torque removal test) was performed as an indicator for the presence ofosseointegration and as a test for the mechanical property of bone-implant interface, because the torsion appearsto be primarily probing the interface mechanics.Results: Removal torque mean values in all studied groups (uncoated and coated with collagen at two and sixhealing intervals were increasing with advancing time (higher at 6 than 2 weeks periods). And coated implantshowed high value in comparison to control. Results have shown that positive reaction for OC&GHR was expressedby osteoblast cells (OB)at implants coated with collagen ,indicating that bone formation &maturation wasaccelerated by adding biological materials as a modification modality of implant surface..Conclusion: Immunohistochemical findings revealed high positive expression range from strong to moderate ofosteocalcin and GHR in coated implant in comparison to uncoated specialy in early periods.

Listing 1 - 10 of 28 << page
of 3
>>
Sort by
Narrow your search

Resource type

article (28)


Language

English (19)

Arabic (4)

Arabic and English (4)


Year
From To Submit

2019 (2)

2018 (1)

2017 (4)

2016 (5)

2014 (3)

More...